Article
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Clinical pharmacology and therapeutics - 1 Sept 2016
Scott S A, Collet J-P, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini A S, Sharma S K, Desnick R J, Fuster V, Hajjar R J, Montalescot G, Hulot J-S
Abstract excerpt
Interindividual variability in platelet aggregation is common among patients treated with clopidogrel and both high on-treatment platelet reactivity (HTPR) and low on-treatment platelet reactivity (LTPR) increase risks for adverse clinical outcomes. CYP2C19 influences clopidogrel response but only accounts for ∼12% of the variability in platelet reactivity. To identify novel variants implicated in on-treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.